Proficio Capital Partners LLC Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Proficio Capital Partners LLC acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 19,952 shares of the company's stock, valued at approximately $376,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC boosted its holdings in Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after purchasing an additional 511,256 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Nurix Therapeutics in the third quarter worth $7,879,000. Patient Square Capital LP purchased a new stake in shares of Nurix Therapeutics in the third quarter worth $7,320,000. Wellington Management Group LLP boosted its stake in Nurix Therapeutics by 8.8% during the third quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after buying an additional 280,240 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after buying an additional 235,971 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company's stock, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares of the company's stock, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,326 shares of company stock worth $213,449. 7.20% of the stock is owned by insiders.

Remove Ads

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock traded down $0.40 during trading on Friday, hitting $12.15. The company's stock had a trading volume of 623,319 shares, compared to its average volume of 896,829. Nurix Therapeutics, Inc. has a 52 week low of $11.90 and a 52 week high of $29.56. The company has a fifty day simple moving average of $16.34 and a two-hundred day simple moving average of $20.37. The company has a market capitalization of $922.03 million, a PE ratio of -4.20 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. As a group, analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NRIX shares. HC Wainwright raised their target price on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $35.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Needham & Company LLC dropped their price target on Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus increased their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $30.88.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.